Cargando…

Remission of Severe Myasthenia Gravis After Massive-Dose Vitamin D Treatment

Patient: Female, 49 Final Diagnosis: Myasthenia Gravis Symptoms: Muscle weakness • shortness of breath Medication: — Clinical Procedure: Vitamin D Specialty: Endocrinology and Metabolic OBJECTIVE: Unusual or unexpected effect of treatment BACKGROUND: Vitamin D has been shown to be related to autoimm...

Descripción completa

Detalles Bibliográficos
Autor principal: Cadegiani, Flávio Adsuara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Scientific Literature, Inc. 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4734680/
https://www.ncbi.nlm.nih.gov/pubmed/26822380
http://dx.doi.org/10.12659/AJCR.894849
Descripción
Sumario:Patient: Female, 49 Final Diagnosis: Myasthenia Gravis Symptoms: Muscle weakness • shortness of breath Medication: — Clinical Procedure: Vitamin D Specialty: Endocrinology and Metabolic OBJECTIVE: Unusual or unexpected effect of treatment BACKGROUND: Vitamin D has been shown to be related to autoimmune diseases, such as multiple sclerosis and psoriasis. Correlations have been reported between vitamin D levels and prevalence and severity of other autoimmune disorders, and also between vitamin D therapy and disease improvement and remission. CASE REPORT: This is a case report of a patient with severe and refractory myasthenia gravis (MG) who followed a “high-dose vitamin D treatment”, a massive-dose treatment (80 000 to 120 000 IU/day) promoted by a medical center in Brazil (but still not proven), and she had her first complete remission after this type of treatment with increased vitamin D serum levels (400 to 700 ng/mL). CONCLUSIONS: This case report may reinforce the reported correlation between vitamin D level and disease severity and introduces a possible new use for vitamin D as a potential target for treating autoimmune diseases. We recommend large, double-blind, placebo-controlled, randomized studies using high-dose vitamin D treatment for refractory autoimmune diseases to reliably assess this pharmacotherapy target for these diseases.